Which has preferable earnings and valuation, EMBC or SNWV?

Embecta has higher revenue and earnings than Sanuwave Health. Embecta is trading at a lower price-to-earnings ratio than Sanuwave Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Embecta $1.04B 0.19 $95.40M $1.90 1.73 Sanuwave Health $44.34M 1.15 $11.81M $0.33 17.97

Is EMBC or SNWV more profitable?

Sanuwave Health has a net margin of 35.96% compared to Embecta's net margin of 10.73%. Embecta's return on equity of -23.96% beat Sanuwave Health's return on equity. Company Net Margins Return on Equity Return on Assets Embecta 10.73% -23.96% 14.12% Sanuwave Health 35.96% -450.56% 44.87%

Is SNWV or PDEX more profitable?

Sanuwave Health has a net margin of 35.96% compared to Pro-Dex's net margin of 16.08%. Pro-Dex's return on equity of 22.78% beat Sanuwave Health's return on equity. Company Net Margins Return on Equity Return on Assets Sanuwave Health 35.96% -450.56% 44.87% Pro-Dex 16.08% 22.78% 14.30%

Sanuwave Health (SNWV) Competitors

$5.93 +0.01 (+0.17%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$5.96 +0.03 (+0.51%)

As of 07/24/2026 07:34 PM Eastern

Compare

SNWV vs. FOCL, LUCD, EMBC, KRMD, and PDEX

Should you buy Sanuwave Health stock or one of its competitors? MarketBeat compares Sanuwave Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sanuwave Health include FocalTherics (FOCL), Lucid Diagnostics (LUCD), Embecta (EMBC), KORU Medical Systems (KRMD), and Pro-Dex (PDEX). These companies are all part of the "medical equipment" industry.

How does Sanuwave Health compare to FocalTherics?

FocalTherics (NASDAQ:FOCL) and Sanuwave Health (NASDAQ:SNWV) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

FocalTherics currently has a consensus price target of $9.00, indicating a potential upside of 49.25%. Sanuwave Health has a consensus price target of $51.00, indicating a potential upside of 760.03%. Given Sanuwave Health's higher probable upside, analysts plainly believe Sanuwave Health is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FocalTherics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Sanuwave Health	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

FocalTherics has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market. Comparatively, Sanuwave Health has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market.

In the previous week, FocalTherics had 1 more articles in the media than Sanuwave Health. MarketBeat recorded 2 mentions for FocalTherics and 1 mentions for Sanuwave Health. FocalTherics' average media sentiment score of 1.12 beat Sanuwave Health's score of 0.47 indicating that FocalTherics is being referred to more favorably in the media.

Company	Overall Sentiment
FocalTherics	Positive
Sanuwave Health	Neutral

62.7% of FocalTherics shares are held by institutional investors. Comparatively, 42.5% of Sanuwave Health shares are held by institutional investors. 10.1% of FocalTherics shares are held by company insiders. Comparatively, 14.4% of Sanuwave Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Sanuwave Health has a net margin of 35.96% compared to FocalTherics' net margin of -41.47%. FocalTherics' return on equity of -137.61% beat Sanuwave Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FocalTherics	-41.47%	-137.61%	-40.62%
Sanuwave Health	35.96%	-450.56%	44.87%

Sanuwave Health has lower revenue, but higher earnings than FocalTherics. FocalTherics is trading at a lower price-to-earnings ratio than Sanuwave Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FocalTherics	$74.07M	3.05	-$29.25M	-$0.81	N/A
Sanuwave Health	$44.34M	1.15	$11.81M	$0.33	17.97

Summary

Sanuwave Health beats FocalTherics on 8 of the 14 factors compared between the two stocks.

How does Sanuwave Health compare to Lucid Diagnostics?

Sanuwave Health (NASDAQ:SNWV) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Sanuwave Health has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

Sanuwave Health currently has a consensus target price of $51.00, indicating a potential upside of 760.03%. Lucid Diagnostics has a consensus target price of $4.19, indicating a potential upside of 361.38%. Given Sanuwave Health's higher possible upside, research analysts plainly believe Sanuwave Health is more favorable than Lucid Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanuwave Health	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Sanuwave Health has a net margin of 35.96% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat Sanuwave Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanuwave Health	35.96%	-450.56%	44.87%
Lucid Diagnostics	-876.72%	N/A	-116.26%

Sanuwave Health has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Sanuwave Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanuwave Health	$44.34M	1.15	$11.81M	$0.33	17.97
Lucid Diagnostics	$5.13M	35.90	-$58.01M	-$0.47	N/A

In the previous week, Lucid Diagnostics had 1 more articles in the media than Sanuwave Health. MarketBeat recorded 2 mentions for Lucid Diagnostics and 1 mentions for Sanuwave Health. Lucid Diagnostics' average media sentiment score of 0.58 beat Sanuwave Health's score of 0.47 indicating that Lucid Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sanuwave Health	Neutral
Lucid Diagnostics	Positive

42.5% of Sanuwave Health shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 14.4% of Sanuwave Health shares are owned by insiders. Comparatively, 6.9% of Lucid Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Sanuwave Health beats Lucid Diagnostics on 10 of the 17 factors compared between the two stocks.

How does Sanuwave Health compare to Embecta?

Embecta (NASDAQ:EMBC) and Sanuwave Health (NASDAQ:SNWV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Sanuwave Health has a net margin of 35.96% compared to Embecta's net margin of 10.73%. Embecta's return on equity of -23.96% beat Sanuwave Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	10.73%	-23.96%	14.12%
Sanuwave Health	35.96%	-450.56%	44.87%

Embecta has higher revenue and earnings than Sanuwave Health. Embecta is trading at a lower price-to-earnings ratio than Sanuwave Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.04B	0.19	$95.40M	$1.90	1.73
Sanuwave Health	$44.34M	1.15	$11.81M	$0.33	17.97

In the previous week, Embecta had 33 more articles in the media than Sanuwave Health. MarketBeat recorded 34 mentions for Embecta and 1 mentions for Sanuwave Health. Sanuwave Health's average media sentiment score of 0.47 beat Embecta's score of 0.10 indicating that Sanuwave Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Embecta	Neutral
Sanuwave Health	Neutral

93.8% of Embecta shares are held by institutional investors. Comparatively, 42.5% of Sanuwave Health shares are held by institutional investors. 1.3% of Embecta shares are held by company insiders. Comparatively, 14.4% of Sanuwave Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Embecta has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Sanuwave Health has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market.

Embecta currently has a consensus price target of $11.00, indicating a potential upside of 234.35%. Sanuwave Health has a consensus price target of $51.00, indicating a potential upside of 760.03%. Given Sanuwave Health's stronger consensus rating and higher possible upside, analysts plainly believe Sanuwave Health is more favorable than Embecta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Sanuwave Health	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Sanuwave Health beats Embecta on 11 of the 17 factors compared between the two stocks.

How does Sanuwave Health compare to KORU Medical Systems?

Sanuwave Health (NASDAQ:SNWV) and KORU Medical Systems (NASDAQ:KRMD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Sanuwave Health has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, KORU Medical Systems has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

42.5% of Sanuwave Health shares are owned by institutional investors. Comparatively, 58.6% of KORU Medical Systems shares are owned by institutional investors. 14.4% of Sanuwave Health shares are owned by company insiders. Comparatively, 18.5% of KORU Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sanuwave Health has a net margin of 35.96% compared to KORU Medical Systems' net margin of -5.27%. KORU Medical Systems' return on equity of -13.61% beat Sanuwave Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanuwave Health	35.96%	-450.56%	44.87%
KORU Medical Systems	-5.27%	-13.61%	-8.33%

Sanuwave Health has higher revenue and earnings than KORU Medical Systems. KORU Medical Systems is trading at a lower price-to-earnings ratio than Sanuwave Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanuwave Health	$44.34M	1.15	$11.81M	$0.33	17.97
KORU Medical Systems	$43.26M	4.07	-$2.64M	-$0.05	N/A

Sanuwave Health currently has a consensus target price of $51.00, indicating a potential upside of 760.03%. KORU Medical Systems has a consensus target price of $7.25, indicating a potential upside of 89.30%. Given Sanuwave Health's higher probable upside, analysts plainly believe Sanuwave Health is more favorable than KORU Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanuwave Health	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
KORU Medical Systems	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, KORU Medical Systems had 1 more articles in the media than Sanuwave Health. MarketBeat recorded 2 mentions for KORU Medical Systems and 1 mentions for Sanuwave Health. KORU Medical Systems' average media sentiment score of 0.93 beat Sanuwave Health's score of 0.47 indicating that KORU Medical Systems is being referred to more favorably in the news media.

Company	Overall Sentiment
Sanuwave Health	Neutral
KORU Medical Systems	Positive

Summary

Sanuwave Health beats KORU Medical Systems on 9 of the 17 factors compared between the two stocks.

How does Sanuwave Health compare to Pro-Dex?

Sanuwave Health (NASDAQ:SNWV) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

Sanuwave Health has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, Pro-Dex has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

Sanuwave Health presently has a consensus price target of $51.00, indicating a potential upside of 760.03%. Pro-Dex has a consensus price target of $70.00, indicating a potential upside of 27.43%. Given Sanuwave Health's stronger consensus rating and higher possible upside, equities analysts plainly believe Sanuwave Health is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanuwave Health	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Sanuwave Health has higher earnings, but lower revenue than Pro-Dex. Pro-Dex is trading at a lower price-to-earnings ratio than Sanuwave Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanuwave Health	$44.34M	1.15	$11.81M	$0.33	17.97
Pro-Dex	$66.59M	2.63	$8.98M	$3.62	15.17

Sanuwave Health has a net margin of 35.96% compared to Pro-Dex's net margin of 16.08%. Pro-Dex's return on equity of 22.78% beat Sanuwave Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanuwave Health	35.96%	-450.56%	44.87%
Pro-Dex	16.08%	22.78%	14.30%

42.5% of Sanuwave Health shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 14.4% of Sanuwave Health shares are owned by insiders. Comparatively, 45.9% of Pro-Dex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Pro-Dex had 2 more articles in the media than Sanuwave Health. MarketBeat recorded 3 mentions for Pro-Dex and 1 mentions for Sanuwave Health. Pro-Dex's average media sentiment score of 1.15 beat Sanuwave Health's score of 0.47 indicating that Pro-Dex is being referred to more favorably in the news media.

Company	Overall Sentiment
Sanuwave Health	Neutral
Pro-Dex	Positive

Summary

Sanuwave Health beats Pro-Dex on 9 of the 16 factors compared between the two stocks.

Get Sanuwave Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNWV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNWV vs. The Competition

Export

Metric	Sanuwave Health	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$50.99M	$8.49B	$6.87B	$12.26B
Dividend Yield	N/A	2.52%	2.67%	9.79%
P/E Ratio	17.97	18.51	27.14	23.64
Price / Sales	1.15	5.78	517.06	88.99
Price / Cash	3.49	18.17	50.54	59.64
Price / Book	31.21	3.19	10.28	6.07
Net Income	$11.81M	$230.22M	$3.60B	$331.99M
7 Day Performance	-7.20%	21.66%	-1.27%	-0.63%
1 Month Performance	-22.28%	20.22%	-0.37%	-2.00%
1 Year Performance	-84.34%	-4.55%	18.30%	13.62%

Sanuwave Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNWV Sanuwave Health	2.6511 of 5 stars	$5.93 +0.2%	$51.00 +760.0%	-83.9%	$50.99M	$44.34M	17.97	40
FOCL FocalTherics	3.4147 of 5 stars	$5.43 -0.2%	$9.00 +65.7%	N/A	$203.72M	$74.07M	N/A	230	Positive News
LUCD Lucid Diagnostics	3.1908 of 5 stars	$0.95 -6.4%	$4.19 +340.7%	-17.5%	$192.95M	$5.13M	N/A	70
EMBC Embecta	4.3963 of 5 stars	$3.25 -3.0%	$11.00 +238.5%	-71.1%	$192.82M	$1.04B	1.71	1,850	Trending News
KRMD KORU Medical Systems	3.5602 of 5 stars	$4.11 -3.1%	$7.25 +76.4%	+9.1%	$188.78M	$41.13M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNWV) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sanuwave Health (SNWV) Competitors

SNWV vs. FOCL, LUCD, EMBC, KRMD, and PDEX

How does Sanuwave Health compare to FocalTherics?

Summary

How does Sanuwave Health compare to Lucid Diagnostics?

Summary

How does Sanuwave Health compare to Embecta?

Summary

How does Sanuwave Health compare to KORU Medical Systems?

Summary

How does Sanuwave Health compare to Pro-Dex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNWV vs. The Competition

Sanuwave Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sanuwave Health (SNWV) Competitors

SNWV vs. FOCL, LUCD, EMBC, KRMD, and PDEX

How does Sanuwave Health compare to FocalTherics?

Do analysts prefer FOCL or SNWV?

Which has more risk & volatility, FOCL or SNWV?

Does the media favor FOCL or SNWV?

Do institutionals & insiders have more ownership in FOCL or SNWV?

Is FOCL or SNWV more profitable?

Which has better valuation and earnings, FOCL or SNWV?

Summary

How does Sanuwave Health compare to Lucid Diagnostics?

Which has more volatility and risk, SNWV or LUCD?

Do analysts rate SNWV or LUCD?

Is SNWV or LUCD more profitable?

Which has preferable valuation and earnings, SNWV or LUCD?

Does the media refer more to SNWV or LUCD?

Do insiders & institutionals have more ownership in SNWV or LUCD?

Summary

How does Sanuwave Health compare to Embecta?

Is EMBC or SNWV more profitable?

Which has preferable earnings and valuation, EMBC or SNWV?

Does the media refer more to EMBC or SNWV?

Do insiders and institutionals have more ownership in EMBC or SNWV?

Which has more risk and volatility, EMBC or SNWV?

Do analysts prefer EMBC or SNWV?

Summary

How does Sanuwave Health compare to KORU Medical Systems?

Which has more volatility & risk, SNWV or KRMD?

Do institutionals & insiders have more ownership in SNWV or KRMD?

Is SNWV or KRMD more profitable?

Which has better valuation & earnings, SNWV or KRMD?

Do analysts recommend SNWV or KRMD?

Does the media prefer SNWV or KRMD?

Summary

How does Sanuwave Health compare to Pro-Dex?

Which has more volatility and risk, SNWV or PDEX?

Do analysts recommend SNWV or PDEX?

Which has higher earnings and valuation, SNWV or PDEX?

Is SNWV or PDEX more profitable?

Do institutionals and insiders have more ownership in SNWV or PDEX?

Does the media prefer SNWV or PDEX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNWV vs. The Competition

Sanuwave Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools